Targeting the Future of Pancreatic Cancer Care: RAS, Biomarkers, and Emerging Therapies

With updates from the 2026 ASCO Annual Conference signaling long-awaited progress in pancreatic cancer, expert faculty review and discuss recent advances that may influence therapeutic decision-making in a historically chemotherapy-centered field. They examine the current role and limitations of multiagent chemotherapy, the growing importance of early germline and somatic testing, and emerging data for RAS-targeted therapies, including pan-RAS inhibition and allele-specific approaches. Faculty also discuss how molecular subsets such as KRAS wild-type disease, NRG1 fusions, CLDN18.2 expression, MTAP loss, and other actionable alterations may shape future treatment selection, sequencing, clinical trial enrollment, and supportive care planning for patients with pancreatic cancer.